Pharma

  • Most Topular Stories

  • Drugmakers don't have apps for that--yet

    News
    tracy
    15 May 2012 | 10:46 am
    Mobile health apps are hot--or at least a hot topic in healthcare circles. Apple's app store boasts some 18,000 in its health and medical categories, and no doubt more come online weekly. Sadly for pharma, only a small fraction of those were developed by drugmakers, or even with particular drugs in mind. Opinions about apps abound, as do arguments over whether apps themselves can do much for patient health. (Ask anyone who's downloaded a calorie-counting program about that one.) What people do agree on is that drugmakers are missing the boat. Most companies are sitting poolside, at…

  • Lipitor R.I.P. Infographic

    Pharma Marketing Blog
    12 May 2012 | 7:48 am

  • Expert Group Recommend That World Health Assembly Should Adopt An International Convention On Global Health R&D

    Pharma Industry / Biotech Industry News From Medical News Today
    16 May 2012 | 3:00 am
    The expert working group advising WHO on research and development has recommended the May 2012 World Health Assembly adopt an international convention on research and development (R&D) that will bind member states to action and catalyze new knowledge for diseases that primarily affect the global poor but for which patents provide insufficient market incentives...

  • Genes Might Be Key to Parkinson's Spread

    Drugs.com - Daily MedNews
    15 May 2012 | 4:05 pm
    TUESDAY, May 15 -- Researchers have identified gene variants that speed the progression of Parkinson's disease, and they say their findings could help identify patients who would benefit most from early treatment. The researchers, from the...

  • Groundbreaking Alzheimer's Disease Prevention Trial Announced

    Drugs.com - Pharma News
    15 May 2012 | 1:46 pm
    Study of Novel Anti-Amyloid Therapy Will Help Launch New Research Era   PHOENIX, May 15, 2012 /PRNewswire/ -- In collaboration with the National Institutes of Health (NIH), Banner Alzheimer's Institute (BAI), University of Antioquia in Colombia...
  • add this feed to my.Alltop

    News

  • Drugmakers don't have apps for that--yet

    tracy
    15 May 2012 | 10:46 am
    Mobile health apps are hot--or at least a hot topic in healthcare circles. Apple's app store boasts some 18,000 in its health and medical categories, and no doubt more come online weekly. Sadly for pharma, only a small fraction of those were developed by drugmakers, or even with particular drugs in mind. Opinions about apps abound, as do arguments over whether apps themselves can do much for patient health. (Ask anyone who's downloaded a calorie-counting program about that one.) What people do agree on is that drugmakers are missing the boat. Most companies are sitting poolside, at…

  • U.K. officials demand action on worsening drug shortages

    tracy
    15 May 2012 | 10:22 am
    Drug shortages are plaguing the U.K. as well as the U.S., to the point where British lawmakers are calling for action against parallel trade. Drugmakers have tried to stop exports of drugs intended for the U.K. market to no avail, so the All-Party Pharmacy Group wants the government to consider curbing those exports. Report

  • Private equity firms snap up 50% of Rottapharm

    tracy
    15 May 2012 | 10:18 am
    Italy's Rovati family has found its new partners, Bloomberg sources say. Two private equity firms will buy a 50% stake in the family's drugmaker Rottapharm, in a deal that values the company at about €1.7 billion ($2.2 billion). Under the agreement, Avista Capital Partners and Clessidra Capital Partners will each own a 25% stake in the company, leaving the Rovatis majority control. The family had been hunting for minority investors since last year. At a $2.2 billion valuation, this deal falls short of the family's asking price; the Rovatis had valued their company at around…

  • Merck KGaA reveals $385M in cuts as Geneva protests continue

    tracy
    15 May 2012 | 9:59 am
    Merck Serono employees in Geneva may have won a battle, but do they have any hope of winning the war? Looking at the cost-cutting numbers Merck KGaA laid out today could be disheartening. After reporting a 48% decline in first-quarter profits (skewed by a one-time gain last year), the German company said it's aiming for €300 million ($385 million) in pharma-related savings by 2014--and €120 million of that comes from shuttering Serono's Geneva site. The now-unionized workers at Merck Serono's Swiss headquarters are fighting that shutdown, which they say endangers 1,250…

  • Payers likely to throw up hurdles to Pfizer's new RA drug

    tracy
    15 May 2012 | 9:20 am
    You know that old adage: The one with the gold makes the rules? That's increasingly true in the drug business. The FDA may be a new drug's biggest hurdle, but payers are throwing up more obstacles as high-tech treatments get pricier and healthcare costs keep rising. For the latest exhibit, look no further than Pfizer's ($PFE) anticipated rheumatoid arthritis treatment tofacitinib. After an FDA advisory panel voted in favor of the drug last week, Reimbursement Intelligence surveyed 30 big payers, asking how they'd manage access to the new treatment if it wins final approval.
 
  • add this feed to my.Alltop

    Pharma Industry / Biotech Industry News From Medical News Today

  • Expert Group Recommend That World Health Assembly Should Adopt An International Convention On Global Health R&D

    16 May 2012 | 3:00 am
    The expert working group advising WHO on research and development has recommended the May 2012 World Health Assembly adopt an international convention on research and development (R&D) that will bind member states to action and catalyze new knowledge for diseases that primarily affect the global poor but for which patents provide insufficient market incentives...

  • The New Pharmacovigilance Legislation Will Impact US And European Drug Manufacturers

    11 May 2012 | 7:00 am
    The Pharmacovigilance Legislation Will Come into Effect in July As the European Medicines Agency's new PV (pharmacovigilance) Legislation implementation date of July 2012 approaches, US and European pharmaceutical and biotech companies need to ask themselves if they are ready for the changes that lie ahead, says Paul Beninger, MD, FACP, Vice President, Global Patient Safety, Genzyme...

  • PETA Grant Enables Scientists To Guide Chinese Officials In Non-Animal Test Use

    11 May 2012 | 3:00 am
    Chinese officials are in the final stages of approving the use of the country's very first non-animal test method for cosmetics ingredients, thanks to guidance from scientists funded by PETA. The 3T3 Neutral Red Uptake Phototoxicity Assay, which tests chemicals for their potential toxicity when they come into contact with sunlight and is already in widespread use in the U.S. and the E.U...

  • Identifying Drugs That Could Help Fight Broad Range Of Viruses

    8 May 2012 | 2:00 am
    Results of a new study demonstrate the feasibility of a novel strategy in drug discovery: screening large numbers of existing drugs - often already approved for other uses - to see which ones activate genes that boost natural immunity. Using an automated, high-volume screening technique, researchers at Washington University School of Medicine in St...

  • Drug Safety Monitoring Should Be Expanded After Approval

    4 May 2012 | 3:00 am
    Pharmaceutical drugs approved by the Food and Drug Administration (FDA) but later re-called from the market - such as the antidiabetic drug Avandia and pain-reliever Vioxx - were the impetus for an Institute of Medicine committee report, recommending that the FDA take proactive steps to continue monitoring drugs' safety after initial approval and throughout their time on the market...
  • add this feed to my.Alltop

    Drugs.com - Daily MedNews

  • Genes Might Be Key to Parkinson's Spread

    15 May 2012 | 4:05 pm
    TUESDAY, May 15 -- Researchers have identified gene variants that speed the progression of Parkinson's disease, and they say their findings could help identify patients who would benefit most from early treatment. The researchers, from the...

  • Blacks, Hispanics Have Higher Colon Polyp Risk Than Previously Thought

    15 May 2012 | 4:05 pm
    TUESDAY, May 15 -- Black and Hispanic Americans are far more likely than whites to develop precancerous colorectal polyps, a new study finds. Researchers analyzed data from more than 5,000 men and women aged 50 and older who had a first-time...

  • Asthma Cases Continue to Rise in U.S., Affecting Millions

    15 May 2012 | 3:05 pm
    TUESDAY, May 15 -- Asthma continues to take its toll on Americans, with almost 19 million adults (8.2 percent) suffering from the disorder in 2010, according to a report released Tuesday by the U.S. Centers for Disease Control and Prevention. The...

  • Trial Set to See if Drug Can Prevent Alzheimer's

    15 May 2012 | 3:05 pm
    TUESDAY, May 15 -- Researchers are preparing to test an experimental drug in people genetically primed to develop Alzheimer's disease. The best-scenario hope is that the drug will lead to a way of preventing the progressive brain-wasting disease,...

  • Beijing's Olympic Smog Shows Pollution's Effect on Health

    15 May 2012 | 3:05 pm
    TUESDAY, May 15 -- With the 2012 Olympics set to begin in London this summer, a new study on air quality during the 2008 Beijing Olympics delivers an important public health message: Reducing air pollution levels could lower the risk of heart...
 
  • add this feed to my.Alltop

    Breaking World Pharma News

  • GlaxoSmithKline to fully acquire Cellzome for £61 million

    15 May 2012 | 4:00 pm
    GlaxoSmithKline plc (GSK) has entered into an agreement to acquire those shares it does not currently own in Cellzome, a leader in the development and advancement of proteomics technologies, for £61 million (US$99 million) in cash.

  • Bristol-Myers Squibb Foundation Announces $15 Million Expansion of Together on Diabetes® to China and India

    15 May 2012 | 4:00 pm
    The Bristol-Myers Squibb Foundation today announced the expansion of its Together on Diabetes® initiative to China and India, pledging $15 million over five years to help these developing nations with rapidly growing numbers of type 2 diabetes patients.

  • Bristol-Myers Squibb and Tsinghua University Enter Strategic Partnership

    15 May 2012 | 3:00 am
    Bristol-Myers Squibb Company (NYSE:BMY) and Tsinghua University of Beijing, China, today announced the formation of a multi-year strategic partnership. Under the agreement, Bristol-Myers Squibb will fund research efforts at Tsinghua University's School of Life Sciences to identify and validate novel targets in oncology and immunoscience.

  • Blood pressure drugs don't protect against colorectal cancer

    14 May 2012 | 4:00 pm
    A new study has found that, contrary to current thinking, taking beta blockers that treat high blood pressure does not decrease a person's risk of developing colorectal cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study also revealed that even long-term use or subtypes of beta blockers showed no reduction of colorectal cancer risk.

  • Statistically significant clinical phase III results of Lu AA21004

    14 May 2012 | 8:00 am
    H. Lundbeck A/S (Lundbeck) today announced positive top-line results from three recently completed phase III clinical studies of Lu AA21004, an investigational drug for the treatment of adults with major depressive disorder (MDD) using dosages from 10 to 20mg.
 
  • add this feed to my.Alltop

    MedWorm: Pharmaceuticals

  • Health Canada Issues Metal Hip Replacement Warning On Metal Hip...

    11 May 2012 | 7:30 pm
    Bernstein Liebhard LLP reports on a metal hip replacement warning issued by Health Canada that cautions patients to be aware of metal hip implant side effects.(PRWeb May 11, 2012)Read the full story at http://www.prweb.com/releases/metal-hip-replacement/warning-hip-implant-side/prweb9500791.htm (Source: PRWeb: Medical Pharmaceuticals)

  • United States Patent and Trademark Office Issues Broader Claims for...

    11 May 2012 | 7:30 pm
    Aruna Biomedical, Inc., the exclusive worldwide commercial licensee of stem cell technology developed at the University of Georgia (UGA), announced today that the US Patent and Trademark Office will...(PRWeb May 11, 2012)Read the full story at http://www.prweb.com/releases/2012/5/prweb9497663.htm (Source: PRWeb: Medical Pharmaceuticals)MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

  • Medical IDs Featured on Recent Episode of The Doctors

    11 May 2012 | 7:30 pm
    Episode of The Doctors features medical ID products from American Medical ID.(PRWeb May 11, 2012)Read the full story at http://www.prweb.com/releases/2012/5/prweb9488055.htm (Source: PRWeb: Medical Pharmaceuticals)

  • Colon health advocate gives $1M to create medical scholarship for African-Americans

    11 May 2012 | 7:30 pm
    A Mississippi native, Dr. J. Steven Blake has not only adapted to his Mount Airy neighborhood, but also built community around his medical practice. And in his eyes, building community has meant raising awareness of colon cancer and the importance of colon health — a subject which Blake not only calls his job, but his passion. From his Germantown Avenue practice, which houses his Mt. Airy Ambulatory Endoscopy Surgery Center and Blake Gastroenterology Associates, Blake has sought to raise awareness... (Source: bizjournals.com Health Care:Pharmaceuticals headlines)

  • Stiefel receives US FDA approval of Fabior™ Foam, 0.1%

    11 May 2012 | 5:08 pm
    Stiefel, a GSK (NYSE:GSK) company, today announced that the US Food and Drug Administration has approved the New Drug Application for Fabior (tazarotene) Foam, 0.1%. (Source: GSK news)
 
  • add this feed to my.Alltop

    Pharma Marketing Blog

  • AstraZeneca's Timely CRESTOR Branded Blog Post: Did It Violate Its Own Policy?

    13 May 2012 | 9:26 am
    It's unusual for a pharmaceutical company to mention a product by brand name on its corporate blog. It's even more unusual to mention BOTH the product AND its indication -- because that would be promotion regulated by the FDA. But AstraZeneca (AZ) has done just that on its "AZ Health Connections" corporate blog.The majority of the post "New CDC data shows drop in number of adults with high cholesterol" submitted by Tom Hushen, AZ's External Communications Manager, talks about CRESTOR, AZ's anti-cholesterol drug. The post may have been ghostwritten for "Dr Philip de Vane, Executive Director of…

  • Lipitor R.I.P. Infographic

    12 May 2012 | 7:48 am

  • Pfizer Throws In the Lipitor Marketing Towel. Repercussions in Job Market Will Be Swift

    10 May 2012 | 7:31 am
    Despite Pfizer's heroic and unprecedented effort to maintain Lipitor's market share after expiry last November and after spending "more than $87 million promoting the medicine, the world's biggest drug company is quietly giving up on its once-great cash cow for good because more generic versions will soon be going on sale" (see this Wall Street Journal story: "Farewell after all, Lipitor").As I reported here on Pharma Marketing Blog on May 2 (see here), Pfizer's Lipitor co-pay card/PBM discount plan failed to meet its goal of maintaining a 40% share of the combined market for Lipitor and its…

  • Have You Met Turbo & Scott? FTC May Want to Meet this eBook for Children Sponsored by Novartis

    8 May 2012 | 1:09 pm
    I just found this tweet from @Novartis:"US only: Have you met Turbo & Scott? Visit http://t.co/yJDtSvhQ to read the TSC eBook or download Barks and Crafts"At first, I thought this would be some kind of Rx branded Web site because it was for "US only," which usually means there's some direct-to-consumer (DTC) Rx product information on the site or closely linked to it. But there isn't any hint of a drug mentioned anywhere that I can find.It's really a site designed for young children who have TSC, "which stands for three big and hard-to-pronounce words, Tuberous Sclerosis Complex."NOTE:…

  • Is 38 Hours Quick Enough to Respond to a Potentially Serious AE Tweet?

    4 May 2012 | 2:28 pm
    Subtitle: JNJ Responds to Adverse Event Reported Directly to @JNJComm via TwitterThere are probably more than 100 pharmaceutical company Twitter accounts such as @JNJComm, which posts news and information from Johnson and Johnson's Corporate Media Relations team (Devon Eyer - @DevonEyer - and Bill Price - @wtprice3).With such a conspicuous presence on Twitter, I am amazed that I haven't noticed very many complaints from consumers directed at these accounts. I'm specifically talking about complaints that relate to adverse drug reactions. Pharma companies are deathly afraid of having to deal…
  • add this feed to my.Alltop

    BioSpace.com Featured News and Stories

  • A Little More Education, a Little Longer Life? Study

    15 May 2012 | 7:00 am
    It's graduation season, and new research offers yet another reason to congratulate someone who has completed at least nine years of education: They're likely to live longer. An unusual, comprehensive study involving 1.2 million Swedes shows that students who were exposed to nine years of education rather than eight had a lower mortality rate after age 40. While the finding suggests an association between...

  • AstraZeneca PLC Slashes 400 More Jobs in Sweden

    15 May 2012 | 7:00 am
    Another 400 jobs will be cut from Anglo-Swedish pharmaceutical manufacturer Astra Zeneca, the company has announced, with the majority of the redundancies in Sdertlje, south of Stockholm. According to the company this is an implementation of the cuts that the company presented in February, when the company announced that 1,100 employees would have to go. We realized already then that it was administrative...

  • Promedior Moves Fibrosis Pipeline to Boston, Hires Shire plc Vet as CEO

    15 May 2012 | 7:00 am
    MALVERN, Penn., May 15, 2012 (BUSINESS WIRE) -- --Company to Relocate Headquarters to Boston Area Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, today announced the appointment of Suzanne L. Bruhn, Ph.D., as President and Chief Executive Officer. Dr. Bruhn takes on the role of CEO at a time when Promedior is rapidly advancing...

  • Gene Therapy Dramatically Extends Mouse Lifespan, Study

    15 May 2012 | 7:00 am
    A new study consisting of inducing cells to express telomerase, the enzyme which -- metaphorically -- slows down the biological clock -- was successful. The research provides a "proof-of-principle" that this "feasible and safe" approach can effectively "improve health span."

  • Achillion Pharmaceuticals, Inc.'s Hepatitis C Drug Gets FDA Fast Track

    15 May 2012 | 7:00 am
    NEW HAVEN, Conn., May 15, 2012 (GlobeNewswire via COMTEX) -- Achillion Pharmaceuticals, Inc. /quotes/zigman/100395/quotes/nls/achn ACHN 2.32% announced today the receipt of a Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACH-3102 as part of an interferon-free regimen for the treatment of chronic hepatitis C (HCV). ACH-3102 is a pan-genotypic second-generation NS5A inhibitor...
  • add this feed to my.Alltop

    Drugs.com - New Drug Approvals

  • Stiefel Receives US FDA Approval of Fabior Foam, 0.1%

    14 May 2012 | 9:05 am
    RESEARCH TRIANGLE PARK, N.C., May 11, 2012 /PRNewswire/ -- Stiefel, a GSK company, today announced that the US Food and Drug Administration has approved the New Drug Application for Fabior (tazarotene) Foam, 0.1%. It is the only retinoid in...

  • MEDA Announces Dymista Approved by the FDA

    2 May 2012 | 12:05 pm
    Göteborg, Sweden--(BUSINESS WIRE)--May 2, 2012 -- The U.S. Food and Drug Administration (FDA) has approved Dymista, a new patented product for treatment of seasonal allergic rhinitis (SAR). In several clinical studies, Dymista has consistently...

  • FDA Approves New Orphan Drug Elelyso to Treat a Form of Gaucher Disease

    1 May 2012 | 6:05 pm
    May 1, 2012 -- The U.S. Food and Drug Administration today approved Elelyso (taliglucerase alfa) for long-term enzyme replacement therapy to treat a form of Gaucher disease, a rare genetic disorder. Gaucher disease occurs in people who do not...

  • FDA Approves Levaquin as an Antibacterial Treatment for Plague

    30 Apr 2012 | 5:04 pm
    April 27, 2012 -- The U.S. Food and Drug Administration today approved Levaquin (levofloxacin) to treat patients with plague, a rare and potentially deadly bacterial infection. The agency also approved the drug to reduce the risk of getting plague...

  • FDA Approves Stendra for Erectile Dysfunction

    27 Apr 2012 | 4:04 pm
    April 27, 2012 -- The U.S. Food and Drug Administration today approved Stendra (avanafil), a new drug to treat erectile dysfunction. Erectile dysfunction is when a man has trouble getting or keeping an erection. An estimated 30 million men in the...
 
 
  • add this feed to my.Alltop

    JNJ BTW

  • Happy Mother’s Day from Johnson & Johnson

    Margaret Gurowitz
    11 May 2012 | 12:19 pm
    As both a Johnson & Johnson employee and a mom (I’m the proud parent of a 12-year old daughter), I’m always interested in the work that our company has done and continues to do to improve the lives of women and children.  Those efforts range from products and information to help mothers over 100 years ago, to today’s efforts like text4baby and MAMA, the partnerships with the United Nations to help women and children, and much more.  Our historical advertising has reflected the Company’s longstanding relationship with mothers (and fathers!), and you can see some of those ads on…

  • New ennTV Episode: Sustainable Products and Improving Health for Women and Children

    Margaret Gurowitz
    10 May 2012 | 2:26 pm
      The new episode of ennTV is out, and this one features some of the ways Johnson & Johnson companies are approaching corporate citizenship and caring for the world environmentally, economically and socially.  The first story is about the Earthwards™ recognized Neutrogena® Naturals line of products, which have natural, sustainable ingredients and packaging.  The second story takes a look at the Company’s partnership with the United Nations Population fund to improve health for women and children, and the third focuses on sustainability in health care through reducing equipment…

  • A Historic and Inspiring Annual Shareholders Meeting

    Devon Eyer
    26 Apr 2012 | 3:40 pm
    Earlier today, we held our Annual Meeting of Shareholders, hosting approximately 1,800 shareholders, retirees and employees in New Brunswick, N.J.   You can watch a replay of the meeting on our website and read a recap of the voting results in an earlier blog post by our Corporate Secretary, Doug Chia. This was my first opportunity to attend the meeting in person, but that wasn’t the only reason it was a historic event!  Johnson & Johnson welcomed its seventh CEO in our history as Alex Gorsky assumed responsibility of incoming CEO from Bill Weldon, who will remain Chairman of the…

  • Voting Results from Johnson & Johnson’s Annual Meeting of Shareholders

    Doug Chia
    26 Apr 2012 | 6:07 am
    By Doug Chia, Assistant General Counsel & Corporate Secretary, Johnson & Johnson Today, Johnson & Johnson held its 124th Annual Meeting of Shareholders in New Brunswick, NJ.  Today’s meeting held special significance in the history of Johnson & Johnson as it marked the transition of the Chief Executive Officer (CEO) position for only the 7th time since the company went public in 1944.  Bill Weldon, Chairman of the Board of Directors and CEO since 2002, handed the CEO title over to Alex Gorsky, previously Vice Chairman of the Executive Committee.  Bill will remain as…

  • MAMA Bangladesh – Getting Information to the Decision Makers

    JNJBTW
    25 Apr 2012 | 12:04 pm
      The Mobile Alliance for Maternal Action (MAMA) is a mobile phone health initiative partnership led by USAID and Johnson & Johnson, with support from BabyCenter, mHealth Alliance and the United Nations Foundation. Recently, members of the MAMA partnership conducted a series of site visits in Bangladesh. This blog post comes from MAMA Global Partnership Director, Kirsten Gagnaire, and is part of their blog tour series reporting on the site visits and experience in Bangladesh.  JNJBTW is happy to host one of the blog posts on that tour. From Kirsten Gagnaire, MAMA Global Partnership…
  • add this feed to my.Alltop

    Pharma Strategy Blog

  • ASCO 2012 Preview – Highlights of key data emerging from Chicago

    MaverickNY
    15 May 2012 | 1:06 pm
    It’s that time of the year again where we cogitate and contemplate on what might be hot at the annual meeting of the American Society of Clinical Oncology (ASCO) before the abstracts are available (they’re released online tomorrow at 6pm … Continue reading →

  • ASCO 2012 Acronym Mania!

    MaverickNY
    14 May 2012 | 11:08 am
    Many of you will remember PSB reader Dr Al Lalani of Regeneron’s guest blog post around this time last year with a quick summary of the key clinical trials at the American Society of Clinical Oncology (ASCO) meeting based on … Continue reading →

  • Ribonucleases (RNase) – clinical applications for cancer therapy

    MaverickNY
    1 May 2012 | 7:14 am
    This is the second post of a two-part mini series on RNases with Dr Laura Strong of Quintessence Biosciences.  If you haven’t yet read it, check out yesterday’s post, which focused on Ribonucleases (RNase) – what are they and why … Continue reading →

  • Ribonucleases (RNase) what are they and why are they relevant to cancer?

    MaverickNY
    30 Apr 2012 | 9:12 am
    At the recent American Association for Cancer Research (AACR) meeting, I had the pleasure of meeting several interesting young scientists and physicians either in the poster halls or in various scientific sessions.  It seemed a great idea to encourage some … Continue reading →

  • Highlights of AACR 2012 – Part 3

    MaverickNY
    23 Apr 2012 | 11:00 am
    Aside from the already published Part 1 and Part 2 blog posts about AACR here on PSB, you can also find some more coverage, including summaries of other topics, on the companion Biotech Strategy Blog, such as the following: SARDs, … Continue reading →
 
  • add this feed to my.Alltop

    PharmaGossip

  • 15 May 2012 | 1:43 pm

    insider
    15 May 2012 | 1:43 pm
    Former Hershey medical researcher charged in federal criminal case A federal judge will have to decide whether it is better for society to have Dr. William J. Zinnanti, a prolific medical researcher, in the hospital laboratory or behind bars. A prison term is on the table for Zinnanti, a former Hershey resident and a graduate of the Penn State College of Medicine, after a criminal charge was filed against him Monday in U.S. Middle District Court in Harrisburg. The charge stems from allegations that a now-defunct Hershey-based business Zinnanti owned, Zinnanti Surgical Design LLC, supplied…

  • How much PR do AZ need?

    insider
    15 May 2012 | 1:38 pm
    Troubled drugs giant AstraZeneca calls in dual agency support The UK’s second largest drug manufacturer is understood to have called in Tonic Life and Red Door Communications for its first UK list, following a seven-month procurement process. However, industry insiders have questioned whether the contracts will last, given the news regarding job cuts and the chief executive’s departure, which came just days after the roster was confirmed. A source said: ‘The future of AstraZeneca’s UK marketing operation is unclear. The whole exercise could be redundant.’ AstraZeneca would not…

  • Ye cannae have yer Yervoy!

    insider
    14 May 2012 | 9:53 am
    Scottish watchdog rejects Yervoy Published on 14/05/12 at 02:55pm The Scottish Medicines Consortium is not recommending Bristol-Myers Squibb’s melanoma treatment Yervoy. The SMC said that Yervoy (ipilimumab), which is seeking a licence to treat advanced melanoma as a second line treatment, was too costly for the NHS in Scotland. The SMC also said that Bristol-Myers Squibb did “not present a sufficiently robust economic case to gain acceptance by SMC”. But the body did say that Yervoy could extend survival compared to an investigational gp100 peptide vaccine used in previously treated…

  • Let the Mediator mess begin

    insider
    14 May 2012 | 9:47 am
    French trial opens in diabetes-diet drug scandal NANTERRE, France (AP) -- The first French trial has begun over a diabetes drug that was also used to lose weight and is suspected in the deaths of at least 500 people. The pharmaceutical group Servier is suspected of "aggravated deception" for hiding the fact that the drug known as Mediator contained an amphetamine called benfluorex - which was taken off the market in 2009 after being found to thicken heart valves. However, another investigation is underway and lawyers for Servier were arguing Monday against holding the current trial claiming…

  • The Pain Connection

    insider
    11 May 2012 | 8:30 am
    U.S. Senate panel launches investigation of painkillers, drug companies The U.S. Senate Committee on Finance has opened a bipartisan investigation into financial relationships between companies that make narcotic painkillers and various nonprofit organizations that have advocated their use for the treatment of pain. Citing investigative reports by the Milwaukee Journal Sentinel/MedPage Today and others, the committee is seeking financial and marketing records from three companies that make opioid drugs, including Oxycontin and Vicodin, and seven national organizations. "It is clear that the…
  • add this feed to my.Alltop

    BioPharma Today

  • Coming In Wednesday's "The Pink Sheet" DAILY - Cornerstone To Acquire EKR Therapeutics

    Wendy Diller
    15 May 2012 | 12:22 pm
    Cornerstone Therapeutics plans to acquire EKR specialty pharma - Decline in use of ESAs like Epogen can increase need for blood transfusions - FDA to award $2 million for research on innovative vaccince clinical trial design -- FDA's CDER ombudsman receives fewer complaints in 2011

  • Latest News From "The Pink Sheet" DAILY - Senate User Fee Package Would Cut Costs, CBO Says

    Wendy Diller
    15 May 2012 | 9:58 am
    PDL BioPharma plans to acquire new royalty assests before key patents expire - Ventrus reports positive Phase III results for dilitiazem - CBO says Senate user fee package will decrease direct spending - Big pharma insiders are pessimistic about pricing going forward - Senator Grassley questions how a hospital bends 340B drug discount rules - Device firms seek more exemptions and pricing flexibility for excise tax

  • Editors' Picks From The World Press

    Wendy Diller
    15 May 2012 | 9:24 am
    Business & Finance Cardinal Health acquires wholesaler Dik Drug MedCityNews.com May 14, 2012 Rottapharm reportedly will sell 50% stake to Avista and Clessidra Bloomberg May 14, 2012 Hospira recalls painkiller lot amid concern of excessive content The Wall Street Journal...

  • Coming In Tuesday's "The Pink Sheet" DAILY

    Wendy Diller
    14 May 2012 | 12:54 pm
    Sen. Grassley, the ranking member on the Senate Judiciary Committee, sends a letter to the University of Alabama Hospital seeking details on how it has recategorized patients to get 340B drug discounts for patients who would not have been eligible otherwise

  • PDUFA Scrubbing: How The House User Fee Bill Got So Agreeably Clean

    Josh
    14 May 2012 | 11:48 am
    Profound reforms to FDA’s mission were set aside, but industry seems poised for several big wins, including (probably) additional antibiotic exclusivity and even a national track and trace standard.
 
  • add this feed to my.Alltop

    Pharmaceutical Online News

  • The Role Of Vacuum Conveying In Pharmaceutical Manufacturing

    15 May 2012 | 8:05 pm
    while keeping product reliability and quality high. More and more often, managers who work with conveying powders and other granular items are looking to adopt automated conveying systems to help solve those problems.

  • Corporate Espionage Is Real — Even In The Pharma Industry

    15 May 2012 | 8:05 pm
    Imagine you spent the past 15 years of your life passionate about finding a cure for Alzheimer’s.You stayed up nights struggling to continue your research, yet you were running out of funding.Knowing your competitors were years behind your research, you finally found your angel investorwho provided the seed capital you needed — but with the time-sensitive precondition that youmust provide a return on investment within two years or they would pull your financing.By Jonathan Snyder

  • Connecting The FDA And Pharma / Biotech Industry

    15 May 2012 | 7:57 pm
    Even with more than 8,800 employees and an annual budget of around $3.2 billion, the FDA’stask of protecting the public health seems daunting, considering the complexity of products beingdeveloped by industry.By Rob Wright

  • U.S. FDA Approves Bristol-Myers Squibb Devens Biologics Manufacturing Facility for Production of ORENCIA®

    15 May 2012 | 11:50 am
    Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s biologics manufacturing facility in Devens, Massachusetts for commercial production of ORENCIA® (abatacept).

  • Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™

    15 May 2012 | 10:11 am
    Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has held an End-of-Phase 2 meeting with the FDA to discuss the proposed safety and efficacy studies to be conducted for the registration of Arimenda (memantine HCl extended release and donepezil HCl) capsules.
  • add this feed to my.Alltop

    Bioresearch Online News

  • Groundbreaking Alzheimer's Disease Prevention Trial Announced

    15 May 2012 | 11:49 pm
    In collaboration with the National Institutes of Health (NIH), Banner Alzheimer’s Institute (BAI), University of Antioquia in Colombia and Genentech, a member of the Roche Group (SIX: RO,ROG;OTCQX:RHHBY), announce the first-ever prevention trial in cognitively healthy individuals who are destined to develop Alzheimer’s disease because of their genetic history.

  • Corporate Espionage Is Real — Even In The Pharma Industry

    15 May 2012 | 8:05 pm
    Imagine you spent the past 15 years of your life passionate about finding a cure for Alzheimer’s.You stayed up nights struggling to continue your research, yet you were running out of funding.Knowing your competitors were years behind your research, you finally found your angel investorwho provided the seed capital you needed — but with the time-sensitive precondition that youmust provide a return on investment within two years or they would pull your financing.By Jonathan Snyder

  • Connecting The FDA And Pharma / Biotech Industry

    15 May 2012 | 7:57 pm
    Even with more than 8,800 employees and an annual budget of around $3.2 billion, the FDA’stask of protecting the public health seems daunting, considering the complexity of products beingdeveloped by industry.By Rob Wright

  • Biomanufacturers Increasing Budgets For Upstream & Downstream Production

    15 May 2012 | 7:48 pm
    Nearly 65% of biomanufacturers are planning to increase their budgets for newtechnologies to improve efficiencies and costs for downstream production, and three outof every five are increasing funding for new upstream production technologies.By Eric Langer, president and managing partner, BioPlan Associates, Inc.

  • CROs & CMOs: Focusing On Innovation

    15 May 2012 | 7:41 pm
    In 2011, innovation was a major topic among the various players in the drugdevelopment industry. Feedback from clients and sponsor-side industry personnelprompted a change in the outsourcing drivers included in the Nice InsightPharmaceutical and Biotechnology Outsourcing survey, such that innovation — or theability to improve in-house capabilities with customized solutions — replacedaccessibility for the 2012 research cycle.By Kate Hammeke, research manager, Nice Insight
  • add this feed to my.Alltop

    PharmiMike

  • Applicant Tracking Systems

    PharmiMike
    10 May 2012 | 5:00 am
    What do you think is the best Applicant Tracking System out there? I’ve just come across this: https://www.zoho.com/recruit/ - it seems quite comprehensive Related posts: Tracking your Campaigns Does anyone know of a good Job application tracking system for Candidates? Twitter Links to LinkedIn

  • With junk tweets, Twitter has no future

    PharmiMike
    19 Mar 2012 | 5:19 am
    Going through the weekend emails, I get a bunch of @suchandsuchhas followed you on twitter. Looking at these, it appears that a large proportion profess to be  ”online marketing gurus” or “entrepreneurs”, a large number have absolutely nothing to do with my business or what I’m interested in. They are just playing a numbers game. “The more followers I have the more important I must be, so if I follow thousands, they will follow me” . Over the weekend my followers included Tennis Updates (I hate tennis), Womens Apparel, (erm..), A bistro somewhere in…

  • Groupme for recruitment / jobs

    PharmiMike
    15 Mar 2012 | 7:21 am
    I’ve been looking at Groupme.com and it seems a very simply way of communicating with your friends using mobile / pc. What I like about it is the simplicity to create groups and then start conversations with specific groups. It can default to SMS is you are using a phone and don’t have data signal, so you dont miss out on important messages. Can this be used for recruitment? Well maybe, I’ve started a couple of groups to play with and I’ll see what they can do. Set up is very easy! Related posts: Save time posting jobs LinkedIn Jobs – why no links? Event: Social…

  • Ignore your emails

    PharmiMike
    28 Feb 2012 | 4:09 am
    In the “old days” your working day was not driven by emails. These days, how many of us spend our day responding to emails and trying to fit in the work we want or need to do, around the demands that land in our in box every day. So, here’s a radical idea. Ignore your emails. OK I don’t mean ignore them completely, but manage them. Try opening your emails at set times of the day. For a start, NOT first thing in the morning, otherwise that sets you off on the wrong path for the day.  How about 10:00am? That’s reasonable. I’m quite sure that most things will…

  • Facebook App – Talent.me

    PharmiMike
    14 Feb 2012 | 6:00 am
    I’ve been looking at the Talent.me application for Facebook. I’ll do a more complete review at some point, but in essence: It’s trying to be a cross between facebook and linkedIn. Indeed it runs as an app, and pulls in your personal data (if you let it) from LinkedIn. Its all pretty straight forward, and ultimately creates a profile page with network, endorsements and a job search powered by Indeed. The jobs unfortunately all appear to be US based, and the searching is basic. Interestingly however, you can add yourself (for free at the moment) as a recruiter by setting up a…
 
 
  • add this feed to my.Alltop

    Medical Brochures Blog

  • Janssen-Cilag's Zytiga

    28 Apr 2012 | 10:38 am
    Product Definition : ZYTIGA® (abiraterone acetate) is for men who have castration-resistant prostate cancer (also known as CRPC, which is defined as prostate cancer that is resistant to medical or... http://medical-brochures.blogspot.com/ the Pharmaceutical Archive of Medical Brochure s, Artwork Designs and Advertisements; to serve Pharmaceutical Marketers, Product Managers, Sales Managers, Medical Representatives, Doctors of different specialties and other Medical Professions.

  • Takeda's Dexilant

    3 Apr 2012 | 11:59 pm
    Product Definition : dexlansoprazole (PPI) Copy writing : The only PPI with a 2nd release that arrives later in the day. Artwork & Concept: Though the concept of the rabbit and the turtle... http://medical-brochures.blogspot.com/ the Pharmaceutical Archive of Medical Brochure s, Artwork Designs and Advertisements; to serve Pharmaceutical Marketers, Product Managers, Sales Managers, Medical Representatives, Doctors of different specialties and other Medical Professions.

  • Dar Al-Dawaa's HairGrow 5% spray

    2 Apr 2012 | 4:50 pm
    Product Definition : Monoxidil 5% Company: Dar Al-Dawaa, Jordan Copy writing : from romanian, any translator ? Artwork & Concept: may be the concept is OK, but there is a problem in the... http://medical-brochures.blogspot.com/ the Pharmaceutical Archive of Medical Brochure s, Artwork Designs and Advertisements; to serve Pharmaceutical Marketers, Product Managers, Sales Managers, Medical Representatives, Doctors of different specialties and other Medical Professions.

  • Caduet

    2 Feb 2012 | 9:57 am
     Product Definition : Caduet contains amlodipine (Amlor), antihypertensive. Copy writing : Demo header the way through risk factors 15th May. Artwork & Concept: very nice artwork,... http://medical-brochures.blogspot.com/ the Pharmaceutical Archive of Medical Brochure s, Artwork Designs and Advertisements; to serve Pharmaceutical Marketers, Product Managers, Sales Managers, Medical Representatives, Doctors of different specialties and other Medical Professions.

  • Polycillin

    27 Jan 2012 | 5:54 am
    Product Definition : Polycillin belongs to a class of antibiotics called penicillins that are used for treating bacterial infections. Other members of this class include amoxicillin (Amoxil),... http://medical-brochures.blogspot.com/ the Pharmaceutical Archive of Medical Brochure s, Artwork Designs and Advertisements; to serve Pharmaceutical Marketers, Product Managers, Sales Managers, Medical Representatives, Doctors of different specialties and other Medical Professions.
  • add this feed to my.Alltop

    Impactiviti blog

  • Why You Need to Build Your Network, Part 1

    Steve Woodruff
    2 May 2012 | 5:46 pm
    At the upcoming SPBT (Society of Pharmaceutical and Biotech Trainers) Conference, I’ll be delivering a workshop on Building Your Own Professional Network. Why is this topic – this practice, this lifestyle – so important? Here’s one reason – a network is more enduring than a company or a job. We’d all like to believe that our current employer will be around forever, on a perpetual growth vector, and that unlimited opportunities will always be before us on the climb up the ladder. I have two words for that: Santa Claus. If I’ve seen nothing else over…

  • Fresh Pharma Jobs for Mid-April

    Steve Woodruff
    20 Apr 2012 | 7:18 am
    A bunch of positions for pharma sales trainers have come on the market here in mid-April, 2012! Here are some links for you: Manager, Cardiovascular Training – Sanofi, Bridgewater, NJ Manager, Diabetes Training – Sanofi, Bridgewater, NJ Manager, Managed Markets Sales Training and Dev – Princeton, NJ Associate Director, Training – Quintiles, Parsippany, NJ Training and Development Manager – VWR, Wayne, PA Sr. Sales Training Manager, Gastroenterology – J&J, Horsham, PA Director, Sales Effectiveness & Training – Teva Pharmaceuticals, Frazer, PA…

  • What Do I Want To Do When I Grow Up?

    Steve Woodruff
    12 Apr 2012 | 7:04 am
    In one form or another, I’ve heard this question a lot in the past few years. And, in fact, I’ve continually asked it of myself. Seems heretical to ask it; but in fact, for people in their 30′s and 40′s – even 50′s – it’s a very common thought. By now, we’ve been in our career for quite some time, and we’re supposed to be on the “right” track heading in the foreordained destination that leads to our personal fulfillment. Yeah, right. Actually, it is only after some years in the work force that we finally begin to ask…

  • The Myth of Corporate Job Security

    Steve Woodruff
    2 Apr 2012 | 9:27 am
    Today is another one of those “Ugggh!” days, when one of my pharma clients is announcing a major new round of layoffs. I’ve seen a lot of these in the past few years, and every time, good people are forced to re-think their career direction. Re-thinking is hard. And in a time when constant marketplace change is the new normal, it’s unavoidable. Permanent employment with ever-stable companies – that’s a thing of the past. Our only security is network security – building a high-quality network of great people, interconnected with other great people.

  • One Pharma Network You Need to Plug Into

    Steve Woodruff
    27 Mar 2012 | 9:11 am
    Way back when the worlds of social media and pharma barely intersected – Impactiviti was there (5+ years ago!). Since then we’ve built quite an extensive network of pharma professionals – including best-in-class service providers for your pharma sales/marketing/training needs! (Impactiviti is a trusted referral network, connecting life sciences clients with hand-selected vendor/partners) And, its free to be part of the Impactiviti network. Here’s how: - Sign up for the Impactiviti Connection pharma e-newsletter, loaded with news and resources for our industry (twice…
  • add this feed to my.Alltop

    Hooked: Ethics, Medicine, and Pharma

  • Bipartisanship in Congress, in Support of Pharma and Device Industries

    15 May 2012 | 11:09 am
    It's often said today that Congress is totally dysfunctional and cannot agree on anything due to the huge partisan culture war. Well, the good news is that there's bipartisan cooperation on at least one issue. The bad news is that it's all in favor of handing the foxes at the pharmaceutical and medical device industries the key to the FDA henhouse. The estimable Merrill Goozner: http://gooznews.com/?p=3914--has blogged about the latest renewal round of the Prescription Drug User Fee Act, where drug firms agree to pay a lot of the freight for running the FDA's drug approval process,…

  • Abbott Labs, Again--More on Recent $1.6 Depakote Settlement

    14 May 2012 | 11:20 am
    Okay, I admit that I'm confused. Last November I posted this about a $1.3B legal settlement paid by Abbott Laboratories over off-label marketing of its drug, valproic acid (Depakote):http://brodyhooked.blogspot.com/2011/11/back-to-standard-form-letter-abbott.htmlNow I learn from our friends at the Health Care Renewal blog that Bloomberg News just announced a $1.6B settlement from Abbott over the same drug for the same…

  • The Things that You're Liable to Hear from Pharma Marketers, It Ain't Necessarily So

    13 May 2012 | 7:08 pm
    I just finished listening to the latest issue of Primary Care Medical Abstracts from my friends Rick Bukata and Jerry Hoffman, which means that I have some more recent articles from the medical literature to comment on. This time the theme is: stuff practitioners believe to be true based on the way that Pharma marketing has flooded the medical airwaves, that may actually not be true at all.Chapter 1: Even if the Prozac class of antidepressants are not necessarily more effective than the older tricyclic antidepressants, at least they're a lot safer. A team from Nottingham, England looked at a…

  • Avastin Continues to Impress for Eye Use

    7 May 2012 | 11:02 am
    A while back I posted on the controversy about the drugs Avastin and Lucentis:http://brodyhooked.blogspot.com/2007/10/retinal-specialists-get-integrity-award.htmlQuick recap: Eye specialists found out almost by accident that a drug intended for cancer, Avastin, was really good for a particular eye condition, wet macular degeneration, and was also quite inexpensive. The maker, Genentech, then marketed a newer cousin of Avastin, called Lucentis, which of course they priced up the wazoo, and tried every trick in the book to get doctors to use it instead of the cheaper Avastin, which remains…

  • Barbara Roberts, "The Truth About Statins"

    5 May 2012 | 8:28 am
    I recently had the privilege of attending the very important conference in Boston called Avoiding Avoidable Care (about how to both improve quality and reduce costs by avoiding the use of nenbeneficial tests and treatments), and there met Dr. Barbara H. Roberts, a cardiologist who heads the Women's Cardiac Center at Miriam Hospital in Providence, RI. I therefore learned about her new book, The Truth About Statins: Risks and Alternatives to Cholesterol-Lowering Drugs (New York: Pocket Books, 2012). I've not yet had time to read the entire book but zeroed in first on Chapter 7, which is titled,…
 
  • add this feed to my.Alltop

    FDA Law Blog

  • Decisions, Decisions, Decisions! Our Updated Labeling Carve-Out Citizen Petition Scorecard

    FDABlog HPM
    16 May 2012 | 2:45 am
    By Kurt R. Karst –       A lot has happened since we last updated our Generic Drug Labeling Carve-Out Citizen Petition Scorecard in October 2011.  At that time, AstraZeneca had only recently submitted two citizen petitions concerning quetiapine fumarate (SEROQUEL and SEROQUEL XR).  Petitions, FDA decisions, lawsuits, and court decisions have abounded since.  So we thought it was high time for us to update our popular scorecard and add a few more bells and whistles, such as FDC Act § 505(j)(10) Citizen Petitions and Approval Precedents (see our previous post here for background),…

  • FSIS Finalizes Rules Mandated by the 2008 Farm Bill

    FDABlog HPM
    14 May 2012 | 7:26 pm
    By Riëtte van Laack – On May 8, 2012, the Food Safety and Inspection Service (“FSIS”) published three sets of regulations mandated by the 2008 Farm Bill: (1) regulations requiring that meat and poultry plants promptly (within 24 hrs) notify FSIS that a contaminated or misbranded product has been released into commerce; (2) regulations requiring that meat and poultry plants prepare written recall procedures; and (3) regulations that require that plants document the mandatory annual reassessment of their HACCP plans, and the reason for actions taken pursuant to that reassessment.  The…

  • FDA Speaks to Nanotech in Cosmetics, Foods, and Drugs

    FDABlog HPM
    14 May 2012 | 3:19 am
    By Ricardo Carvajal - April was a busy month for nanotechnology at FDA.  The agency issued two draft guidance documents worthy of close examination for those with an interest in the use of emerging technologies, including nanotechnology, in the cosmetic and food industries.  Further, FDA denied a citizen petition asking the agency to stop the marketing of sunscreen drug products that contain engineered nanoparticles of zinc oxide and titanium dioxide. The first draft guidance document, Safety of Nanomaterials in Cosmetic Products, begins by emphasizing manufacturers’ responsibility to…

  • House Bill Introduced to Include Medical Devices in the Postmarket Risk Analysis and Identification System

    FDABlog HPM
    10 May 2012 | 8:14 pm
    By Jennifer D. Newberger – On May 7, 2012, Representative Lois Capps introduced the “Sentinel Assurance for Effective Devices Act of 2012” (H.R. 5341), many elements of which were also included in the House of Representatives Energy and Commerce Health Subcommittee user fee bill (see here).  The primary purpose of the bill seems intended to allow FDA to more regularly collect, review, and trend adverse event data for medical devices.  The bill accomplishes this in two ways:  First, it would amend the Federal Food, Drug, and Cosmetic Act (“FDC Act”) to include medical devices in…

  • Garbage Runs, Fake Identities, and Surprise Home Visits: Strategies to Deal With FDA’s Nontraditional Investigative Tools – an HP&M Webinar

    FDABlog HPM
    10 May 2012 | 5:26 pm
    Hyman, Phelps & McNamara P.C. invites you to register for our webinar, “Garbage Runs, Fake Identities, and Surprise Home Visits: Strategies to Deal With FDA's Nontraditional Investigative Tools,” which is scheduled to take place on Wednesday, June 20, 2012 from 12:30 - 2:00 p.m. ET.  From routine on-site inspection to rummaging through trash bins outside your facility, FDA and other government agents have shown increasing willingness to obtain information outside of just conducting regulatory inspections of company facilities.  This webinar will provide an overview of popular,…
  • add this feed to my.Alltop

    PHARMACOSERÍAS Marketing Farmacéutico/Pharmaceutical Marketing

  • Cuadro de "Des_Honor" por "Malas Prácticas" de Marketing.

    15 May 2012 | 5:02 pm
    With Abbott’s $1.5 billion settlement of a whistleblower-initiated case this week, Abbott joins an infamous list of pharma companies that have paid more than one billion dollars to the federal government for illegal marketing practices, including promoting prescription drugs for uses not approved by the FDA, paying financial inducements to increase sales and engaging in practices that pose grave

  • SERVIER: El rey del medicamento francés en el banquillo por 500 muertes

    15 May 2012 | 5:02 pm
    El caso es el mayor escándalo sanitario de la historia moderna de Francia. Los laboratorios Servier, un gigante de la industria farmacéutica europea, vendieron entre 1976 y 2009 cerca de 245 millones de cajas de Mediator, un quitahambre indicado para diabéticos con sobrepeso, pero que era consumido sobre todo por gente sobrada de kilos y sin diabetes. Cinco millones de personas tomaron durante

  • The Biggest R&D Spenders in Biopharma 2011(II)

    15 May 2012 | 5:02 pm
    Click sobre imagen para ampliar.Roche (1º) y Pfizer (2º) encabezan el ranking de inversión en I+D a nivel global.Merck US (5º), Novartis (8º), J&J (10º), Sanofi-Aventis (14ª) y Glaxo (16º) tambien situan entre las 20 primeras.Lilly (24º), Bayer (28º) y Astra Zeneca (29º) ocupan un segundo nivel.Entre las 50 primeras completan lista Abbott (37º), Takeda (39º), Bristol Myers Squib (40º),

  • La muerte de...Carlos Fuentes (no la de Artemio Cruz)

    15 May 2012 | 2:00 pm
    "Yo despierto... Me despierta el contacto de ese objeto frío con el miembro. No sabía que a veces se puede orinar involuntariamente. Permanezco con los ojos cerrados. Las voces más cercanas no se escuchan. Si abro los ojos, ¿podré escucharlas?... Pero los párpados me pesan: dos plomos, cobres en la lengua, martillos en el oído, una... una como plata oxidada en la respiración. Metálico todo

  • The Biggest R&D Spenders in Biopharma 2011(I) / Quiénes y dónde esta la I+D

    14 May 2012 | 5:02 pm
    Click sobre imagen para ampliar.La industria farmacéutica (y biotecnológica), despues de la ICT, es la que más recursos dedica a la I+D.Si se comparan cifras respecto 2002 el incremento es realmente significativo...En el caso de la I+D farmacéutica se localiza, mayoritariamente, en USA, Comunidad Europea (CE) y Japón (en este orden).Ver anterior:The Biggest R&D Spenders in Biopharma 2011(0)
  • add this feed to my.Alltop

    Drug Channels

  • Cardinal Settles with the DEA, while Senators ask for an Inquiry

    15 May 2012 | 8:00 am
    Cardinal Health (NYSE: CAH) made news again today by announcing a settlement with the Drug Enforcement Administation (DEA) regarding its Lakeland, FL, distribution center. See Cardinal Health Brings Resolution to Litigation with DEA Settlement. Regular readers know that I've been very critical of the DEA's aggressive and misguided pursuit of pharmaceutical manufatcurers and wholesalers. For perspective on this current dispute and Cardinal's historical troubles, see February's Cardinal Fights a Misdirected DEA. Read on for some more thoughts on this issue and details of how…

  • BREAKING NEWS: Cardinal Health to Acquire DIK Drug

    14 May 2012 | 8:00 am
    In today's sorta surprising (but not really) M&A news, Cardinal Health (NYSE: CAH) has signed a letter of intent to acquire regional wholesaler Dik Drug. No press release yet, so consider this post to be another Drug Channels exclusive. (The news was confirmed to me by Cardinal's SVP of Public Relations.) This deal is one more step in the long-running consolidation of the U.S. pharmaceutical distribution business. It also helps further boost Cardinal's business with smaller pharmacies. Dik is a closely-held and fairly secretive private company, so there's no official data…

  • Walgreens is Losing Its Battle with Express Scripts

    10 May 2012 | 6:30 am
    Last week, Walgreen (NYSE: WAG) reported another month of dismal sales following its exit from the Express Scripts (NASDAQ: ESRX) pharmacy network. See Walgreens April Sales Decrease 3.7 Percent. The chart below highlights the ignominy of watching Rite Aid (NYSE:RAD) grow more quickly than Walgreens. That must hurt. Last December, Walgreen’s management presented rosy scenarios in which they retained as much as 70% of the Express Script’s business. My back-of-the envelope calculations suggest they actually retained about 15%. Walgreen’s management is hoping for an unlikely miracle during…

  • Armada 2012: Reflections on the Evolving Specialty Marketplace

    8 May 2012 | 6:00 am
    Last week, I attended the always-energizing Armada Specialty Pharmacy Summit in Las Vegas. In violation of standard Vegas rules, I’ll tell you what happened there…or at least the part related to the specialty market. As always, the Irene brothers put on a top-quality event at the Wynn, my personal favorite Vegas hotel. I came away impressed by the diversity and scale of the specialty pharmacy marketplace. Future directions for the specialty pharmacy industry were evident everywhere. Below are four observations from my conversations at the meeting. Special thanks to the many, many Drug…

  • Drug Channels News Roundup: May 2012

    2 May 2012 | 7:30 am
    It’s May! The trees are blooming, the sun is shining, and the birds are singing. But you’d rather stay inside and enjoy my monthly look at noteworthy news stories from the Drug Channels universe, right? News stories...Assemble! A new benefit design for Stark Industries? Humana and Walmart launch a preferred pharmacy network for the commercial market. Loki would be proud. The FDA reminds 108 physician practices not to buy from dubious sources. Really?!? Hulk Smash Buy-and-Bill! UnitedHealth’s Lee Newcomer makes the case against current reimbursement models. Just don't make Dr.
 
  • add this feed to my.Alltop

    Prescription Drug Forums - The People's Medicine Community

  • Sleep paralysis w/ hallucinations

    16 May 2012 | 4:50 am
    Has anyone else experienced sleep paralysis accompanied by hallucinations since starting viibryd? I have been on the medicine for about 4 months now and for the last 2 1/2 months have had several very scary episodes of sleep paralysis... I have never been on a anti-depressant before and never experienced sleep paralysis until i started this medicine. I am a 23 year old female and i take no other meds except a daily multi-vitamin. Ive noticed that if i accidentally miss a viibryd pill i have sleep paralysis... but have also had it on occasions of not missing a pill. It occurs about once a…

  • Systemic Lupus

    16 May 2012 | 4:13 am
    MY SON AGED 22, WAS HAVING SEVERE PAIN IN THE JOINTS AND FATIGUE. WE CONSULTED A RHEUMATOLOGIST. AFTER DETAILED BLOOD STUDIES HE CAME TO THE CONCLUSION THAT MY SON IS HAVING SLE (HIS ANA COUNT WAS 836 AND THE ANA PROFILE INDICATED SLE).FOR LAST 18 MONTHS HE IS TAKING HCQS, PREDMET(PREDNISOLONE WITH METFORMIN), CALCIUM WITH D3,METHOTRAXATE(20MG PER WEEK) AND SOME VITAMIN TABLETS. RECENTLY, HE HAD PROBLEMS WITH CONCENTRATION WITH STUDIES, IRREGULAR SLEEP AND DEPRESSION FEELING. HE CONSULTED A PSYCHIATRIST WITH THE PERMISSION OF HIS REGULAR DOCTOR. THE DOCTOR GAVE HIM SIZODON(RASPIRODON)0.5 MG…

  • Atorvaststain 10mg and Metformin Hydrochloride (as Extended release) 500mg tablets

    16 May 2012 | 4:06 am
    Is there any inforation about the combination of Atorvastatin 10mg + Metformin hydrochloride (as Extended release) 500 mg tablets? If yes pl. provide the details about the combination. - Filed in Metformin - 3 Replies

  • 2012 Oxycodone 30mg Shortage In Florida

    16 May 2012 | 3:59 am
    My spouse, who is in severe, chronic pain, has been a customer of Walgreens for many years. We live in Pinellas County, Florida. Everyday this week we have driven from Walgreen's to Walgreen's trying to fill his prescription for Roxicodone 30mg, to no avail. I cannot get any help from his regular pharmacy. I know that it's dangerous for them to tell a total stranger which store has them in stock, but I don't understand since they know him, why they can't call around or give us any assistance. I am at a total loss as to what to do & would appreciate any information that you could provide. It…

  • why did methadone not show up in urine test

    16 May 2012 | 3:43 am
    I am very concerned. My Dr. started me on methadone at 5 mg 2x per day. 4 days later I had a urine test and the methadone did not show up. now my Dr. is concerned that I am not following treatment and I have been following it as I was told to. does anyone have have any idea as to why methadone would not show up in a pee test? - Filed in Methadone - 24 Replies
  • add this feed to my.Alltop

    News

  • Charge-changing nanoparticles can help kill resistant bacteria

    dgarde
    9 May 2012 | 7:29 am
    While the field of antibiotics has come a long way since the days of Louis Pasteur, the evolution of bacteria has created challenges for doctors trying to treat infections that have become largely drug-resistant. Researchers at MIT and Brigham and Women's Hospital may have found a solution: bombarding bacteria with antibiotics using nanoparticles that can evade the body's defenses. In a paper published in ACS Nano, the researchers explain that while antibiotics strong enough to kill dangerous bacteria exist, getting them to the infection sites can be exceedingly difficult. So,…

  • Nanodelivery could revive failed cancer treatment, 'forgotten' drugs

    dgarde
    9 May 2012 | 6:40 am
    The once-promising wortmannin was a pipeline cancer treatment with high hopes to reach the market. Its fate, however, was a familiar one: High toxicity, poor stability and low solubility torpedoed its progress, and it never established clinical efficacy. Now, thanks to a team of researchers at the University of North Carolina, wortmannin might get a second chance, using nanotechnology that can work around the perils of traditional drug administration. The group reported its proof-of-principle findings in Proceedings of the National Academy of Sciences, finding that a nanoparticle formulation…

  • pSivida gets U.K. nod for behind-the-eye treatment

    dgarde
    9 May 2012 | 5:13 am
    More good news for pSivida ($PSDV): The company's behind-the-eye macular edema treatment, Iluvien, picked up another approval, this time from the U.K.'s Medicines and Healthcare products Regulatory Agency. The treatment uses the company's Durasert platform, an injectable intravitreal insert placed behind the eye to release drugs. Iluvien uses the platform to deposit sub-microgram amounts of fluocinolone acetonide into the eye to treat chronic diabetic macular edema. The U.K. authorization follows one from Austria last month, and the news highlights the treatment's…

  • Patent cliff could create need for novel delivery tech

    dgarde
    8 May 2012 | 9:08 pm
    As blockbusters go off patent and generics companies scramble to compete, novel drug delivery tech could be the difference-maker in the marketplace, Labopharm's Shams Rustom said. Speaking at Interphex, Rustom said genericsmakers can get a leg up in the battle for off-patent profits by implementing new drug delivery methods to make a drug more convenient or bioavailable, in-PharmaTechnologist reports. With many big-time sellers losing their patents in the coming years, this could mean major opportunities for drug delivery firms, Rustom said. Report

  • MonoSol, Midatech tout positive Phase I for insulin film

    dgarde
    8 May 2012 | 8:29 pm
    MonoSol Rx and Midatech's joint venture (dubbed MidaSol, of course) has some good news for its transbuccal insulin film. Phase I trials of Midaform produced positive bioavailability and pharmacokinetic results for the film, the companies said this week. Midaform uses MonoSol's PharmFilm delivery platform, a quick-dissolving mucoadhesive film that allows APIs to be absorbed through the cheek. By loading PharmFilm with nanoparticle-stabilized insulin, the companies hope to provide a solution for patients for whom subcutaneous insulin delivery is unpleasant or impossible. And…
 
  • add this feed to my.Alltop

    Pharmaceutical Sales Drug Representative Jobs Blog

  • On Pharmaceutical Sales Management Consulting Contract

    Clint Cora
    7 May 2012 | 6:32 am
    Pharmaceutical Sales Management I will be on a pharmaceutical sales management consulting contract all this week for a major pharma client.  Of course I can’t reveal the details of what we are doing but if there are any interesting things or observations I can share with your all, I will certainly post them here on this pharmaceutical sales jobs blog. One thing for sure is that the pharmaceutical sales field is changing the way how some aspects of physician detailing and drug sampling are done.  I’ll get to see how one major company is adapting. Of course, this does change the…

  • Former Pharmaceutical Sales Executive Launches Rent To Own Canada Program

    Clint Cora
    2 May 2012 | 6:58 am
    Rent To Own Canada As a former pharmaceutical sales executive, it might be odd that I would expand again in territory that might seem unrelated to pharma. But in many ways, there can be some overlap.  The latest area I’ve expanded into is a rent to own Canada program. What this program basically does is to help those with poor credit or even no credit, become homeowners.  Many new pharmaceutical sales representatives may fit into this category.  They haven’t established good enough credit to qualify for conventional mortgage financing yet. Some are so early in their…

  • New Keynote Available For Pharmaceutical Sales Meetings

    Clint Cora
    16 Feb 2012 | 10:13 am
    photo credit: kahunapulej Now A Motivational Sales Speaker Too I now have a new keynote presentation to add to my overall available speaking programs for pharmaceutical sales audiences and this one will effectively make me a motivational sales speaker. Although I’m primarily known as a motivational speaker as well as a diversity speaker, this new keynote should not come as a big surprise.  Since graduating with my MBA way back in 1985, I started a corporate career that spanned over 20 years. About 14 of those corporate years were in the pharmaceutical industry where I held roles as a…

  • January Is Pharmaceutical Sales Meetings Month

    Clint Cora
    12 Jan 2012 | 2:39 pm
    photo credit: somaya Pharmaceutical Sales Meetings Just in case if you are trying to do any networking with drug reps out there, January is typically sales meetings month when companies have their big first sales force meeting to kickstart the year.  This might even run into February too so don’t be surprised if it’s a bit tricky to catch any of the drug reps in your area right now. But they will be back on territory soon so don’t give up your networking efforts. Take the time to put the concepts learned in ‘How To Get A Dream Job In Pharmaceutical Sales –…

  • Pharmaceutical Sales Jobs Rehires After Layoffs

    Clint Cora
    12 Dec 2011 | 11:27 am
    photo credit: CarbonNYC Pharmaceutical Sales Jobs I will be doing a consulting project for one of the big pharma companies this month and it’s actually a repeat client since I did a similar one for them last year working for their drug representatives for a few days.  In addition to being a business speaker, I also do these consulting projects on the side. I know that they went through a layoff earlier this year but as I scan the names of the drug representatives I’ll be working with this month, I notice a lot of new names. Although there were many of the same names from last…
  • add this feed to my.Alltop

    Latest Featured Articles

  • Pharma a leader in web effectiveness

    Craig Sharp
    14 May 2012 | 8:21 am
    Précis:  Often criticised for not properly adopting new web technologies, pharma proves it knows a thing or two about the corporate website. Six pharma companies have made it into the list of top 20 businesses in this year’s Financial Times Bowen Craggs Index of web effectiveness. The report, which rates websites "that are well built, well integrated with other channels (eg YouTube or social media), present the companies messages most impressively, and serve a range of stakeholders well", is a positive result for pharma – with Roche topping the table at number…

  • Market access: Pharma and the definition of value

    Editor
    7 May 2012 | 8:48 pm
    Précis:  Jan Stojaspal explores the role of value-based pricing in gaining market access There comes a point for patients with advanced forms of Parkinson’s disease when oral medications designed to boost their dopamine levels can no longer adequately control the debilitating shakes, poor balance and muscular stiffness that characterize this progressive disease of the central nervous system. Related Content:  Is value-based pricing an aid to market access? The impact of value-based pricing on market access and patience compliance Image:  Primary Event:  Market…

  • Pharma, adherence, and digital health coaching

    Andrew Tolve
    2 May 2012 | 8:55 am
    Précis:  Andrew Tolve explores how digital health coaching is helping the healthcare industry provide cost-effective services that boost adherence Devising a personal care plan for every patient who walks into a doctor’s office or pharmacy is time- and resource-intensive, not to mention cost-prohibitive given the expense of one-on-one sessions with doctors, nurses, and pharmacists. At the same time, the failure of one-size-fits-all adherence campaigns goes to show that personalized care and individual treatment plans can mean the difference between an adherent and non-adherent…

  • Pharma sales reps and the e-training alternative

    Andrew Tolve
    26 Apr 2012 | 8:26 am
    Précis:  Andrew Tolve examines how virtual sales training can boost selling skills—and save money Related Content:  Special report: Pharma and the iPad Special report: KOLs and pharma Image:  Primary Event:  SFE USA Premium`:  No read more

  • Pharma Sales Teams are full of “dead wood”

    Craig Sharp
    25 Apr 2012 | 4:16 am
    Précis:  Industry research shows that Sales Teams have "significantly more dead wood in the field forces than in other industries" and that company "best practice" may not actually be what's best for your company... As if we weren’t acutely aware of the on-going sales crisis within the pharma industry already, a leading voice in business consultancy has been researching pharma’s sales force performance - and the results are anything but flattering. “There’s significantly more dead wood in pharma field forces compared to other industries.
  • add this feed to my.Alltop

    News

  • MMR and autism: Italy's courts get involved

    selvidge
    10 May 2012 | 6:16 am
    An Italian health news website seems to have reported that an Italian court has ruled that an MMR vaccine caused autism in a child. I am relying on a Google Translate translation of the piece, as I speak no Italian, but it appears that the court has upheld an appeal from the parents for the Ministry of Health to pay compensation "for irreversible complications caused by a vaccination" ("per complicanze irreversibili causate da una vaccinazione"). According to the piece, which reports The Lancet's withdrawal of the Andrew Wakefield paper that linked MMR and autism, and…

  • First 'cross-kingdom' vax effective in PhI

    selvidge
    10 May 2012 | 5:22 am
    NovaDigm Therapeutics is developing a vaccine that could work against both bacteria and fungi, and could even combat resistant bacteria such as methicillin-resistant Staphylococcus aureus, more famously known as MRSA. The vaccine was safe and effective in its second Phase I study, according to results presented at the 15th Annual Conference on Vaccine Research. The vaccine, known as NDV-3, targets an antigen from Candida albicans, the yeast that causes thrush. Antibodies to this antigen also target other bacteria and fungi, and, according to the company, this makes NDV-3 the first…

  • Study: Further insight into Merck HIV vax infection increase

    selvidge
    10 May 2012 | 4:18 am
    Preventive vaccines are designed to prevent disease. As they say in the U.K.--it does exactly what it says on the tin. Or it should. However, a recent study published in the Journal of Infectious Disease confirmed that a vaccine study halted in 2007 showed an increased risk of infection in the first 18 months for subgroups of the men who were vaccinated, but that this difference disappeared after 18 months. The STEP Study was a Phase IIb trial of Merck's ($MRK) V520, an HIV vaccine based on the adenovirus serotype 5 (Ad5, which is a cold virus). The initial analysis showed that the…

  • Pneumococcal vax cuts deaths, but cases tripled

    selvidge
    10 May 2012 | 3:07 am
    It's not often that we report on a doctoral thesis here at FierceVaccines, but this one has hit the headlines--while vaccines against Streptococcus pneumoniae have cut the number of deaths from this bug that can cause pneumonia and meningitis, the number of cases has tripled in the past 50 years. The thesis, written by Erik Backhaus, doctoral student, Sahlgrenska Academy, University of Gothenburg, looked at the changes in invasive pneumococcal disease before and after the introduction of childhood vaccination with the 7 valent pneumococcal conjugate vaccine known as PCV-7 in Sweden. He…

  • Swine flu vax could offer universal flu protection

    selvidge
    9 May 2012 | 3:22 pm
    Flu comes in many forms, from the mild bout of a seasonal bug that can just knock you flat for a week, to the 2009 H1N1 (swine flu) pandemic that killed thousands of people worldwide, to mutations of the H5N1 (bird flu) virus that could be weapons of terror in the future. Researchers in Canada are touting a 2009 swine flu shot as a potential route to a universal vaccine that could target all these forms of influenza, according to data published in Frontiers of Immunology. According to John Schrader, Canada Research Chair in Immunology and director of the University of British Columbia's…
 
  • add this feed to my.Alltop

    News

  • Download our eBook 'Supplying global clinical trials: Keys to avoiding costly delays'

    khardy
    15 May 2012 | 11:10 am
    Getting clinical trials right, and right the first time, is crucial for biopharma companies, especially as the cost of getting a drug to market is skyrocketing. Matthew Herperestimates in "The Truly Staggering Cost Of Inventing New Drugs"--which ran in Forbes in February--that drug development costs have reached the eye-watering level of somewhere between $4 billion and $11 billion. R&D returns have therefore fallen drastically and are around half what they were 10 years ago, explains Ian Shott, managing director and principal consultant at Shott Consulting: "Attrition is…

  • Contract manufacturer Vetter to open new high-tech warehouse

    epalmer
    15 May 2012 | 9:13 am
    Vetter, the German contract manufacturer that specializes in aseptic filling, has invested €35 million ($45 million) in a new temperature controlled warehouse in Ravensburg, Germany, where the company is headquartered. About 400 people will work at the new facility, which the company says in January received manufacturing approval and cGMP certification from the RP Tuebingen, Germany. Like other companies, such as GlaxoSmithKline ($GSK), the Vetter facility has incorporated a number of green energy processes, including solar power, a biogas plant for heating and geothermal technology for…

  • U.K. pharmacy group wants drug exports stopped

    epalmer
    15 May 2012 | 9:03 am
    While other countries have drug shortages tied to manufacturing debacles and plant closures, the U.K. is blaming the problem on parallel trade. The government is being urged by a pharmacy group there to consider banning drug exports.    Because of EU trade rules and a weak pound, wholesalers are sourcing drugs in the U.K. then selling their supplies to countries where they can make more money, Reuters reports. The All-Party Pharmacy Group (APPG) told government officials the problem has gotten worse over the last four years and it needs to find a way to block the practice or…

  • Another pain drug recall for Hospira

    epalmer
    15 May 2012 | 7:56 am
    Hospira ($HSP), which has been trying so hard to make improvements in its manufacturing and quality-control methods in the face of plant problems, has had to recall another lot of medication, this time syringes believed to contain too much of a pain killer. A release from the company posted on the FDA website says Hospira voluntarily recalled a single lot of hydromorphone injection Carpuject after receiving two reports that single-filled cartridge used in the Carpuject contained more than the 1 mL labeled fill volume. The medication was distributed in September and October last year to…

  • Review slams U.K. regulators over breast implant failures

    epalmer
    15 May 2012 | 7:13 am
    The U.K. regulators who should have been there to protect the health of patients, fell down on the job when it came to the silicone breast implants made with substandard materials, received by thousands of women, according to a government review published Monday. The Poly Implant Prothese (PIP) case involved deliberate fraud, so oversight alone wasn't going to prevent the problem, the U.K. health minister acknowledged, but he said the agency could have done more, Reuters reports. The now-defunct French company disclosed that countless women had received breast implants made from…
  • add this feed to my.Alltop

    News

  • Smith & Nephew CEO: Lack of innovation begats plunging industry margins

    mhollmer
    15 May 2012 | 10:38 am
    The medical device industry is boring. It doesn't innovate. And that, rather than government austerity, is why companies continue to face falling margins. Before you write that off as a conclusion coming from an outside consultant, consider that it comes from one of the industry's major figures: Smith & Nephew ($SNN) CEO Olivier Bohuon. Bohuon, CEO since April 2011, tells Financial Times that the industry should essentially stop whining about government cutbacks in funding for health-related services, and blame itself for not coming out with state-of-the-art, game-changing…

  • Boston Sci, Abbott gain European sign-off for stent products & services

    mhollmer
    15 May 2012 | 9:57 am
    With European regulatory approvals in hand, Boston Scientific ($BSX) and Abbott ($ABT) are both debuting stents or stent-related treatment offerings overseas that illustrate how rigorous competition in the space continues to be. Following a CE mark earlier this year, BSX is rolling out its Innova Self-Expanding Bare Metal Stent System in Europe. The stent is designed to treat peripheral vascular lesions in the superficial femoral artery and proximal popliteal artery above the knee. BSX touts this product as a way to avoid other issues that happen when treating arteries above the knee, such as…

  • Sonitus Medical lands $25 million Series D round for hearing device

    dgarde
    15 May 2012 | 9:16 am
    California's Sonitus Medical pulled in $25 million in a Series D round of VC funding, money that the company will put toward its in-the-mouth hearing device. Abingworth, an international life sciences investor, led the round, and Sonitus plans to use the funds to market its SoundBite Hearing System in the U.S. "We view this financing as validation of both the ear, nose and throat market, and Sonitus Medical's emerging leadership in the bone-conduction hearing device category," company CEO Amir Abolfathi said in a statement. Already armed with FDA 501(k)…

  • After quiet Q4, device recalls surge in 2012

    dgarde
    15 May 2012 | 8:22 am
    Recalls of medical devices jumped 160% between the fourth quarter of 2011 and the first quarter of 2012, a not entirely unexpected development after 2011's late-year tranquility, reports the ExpertRECALL Index. The FDA recalled 277 devices in the first quarter, affecting 82 million units, the most in 5 quarters. While that number is high, the quarter-to-quarter increase wasn't terribly jarring to industry watchers, according to ExpertRECALL, because Q4 of 2011 was unprecedentedly quiet on the recall front, with 106 devices recalled. "However, what is troublesome is the dramatic…

  • Cancer Genetics' $48.6M IPO to fuel R&D plus marketing hires

    mhollmer
    15 May 2012 | 8:18 am
    Cancer Genetics will ramp up clinical trials plus expand its sales and marketing staff with an initial public offering the company envisions will haul in close to $49 million. Considering that the IPO markets remain uneven, this is yet another sign that investors see molecular diagnostics as a sure thing that are coming into their own as a vital part of the healthcare system. The New Jersey molecular diagnostics company disclosed the amount in an amended S-1 regulatory filing submitted with the SEC on May 7. Plans call for offering 4 million shares at about $12 per share. Initially, the…
  • add this feed to my.Alltop

    Pharmalot

  • Should A Federal Agency Oversee The DSM?

    Ed Silverman
    15 May 2012 | 8:56 am
    Last week, the American Psychiatric Association unexpectedly backed down from two controversial proposals that would have increased the number of people who could have been diagnosed with psychotic or depressive disorders. The change meant that attenuated psychosis syndrome and mixed anxiety depressive disorder will not be listed in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders, or DSM, to be published next year. The move was greeted with applause by critics who more often accuse the organization of wantonly adding to the list of psychiatric diagnoses that may…

  • How Payers View Pfizer’s Rheumatoid Arthritis Pill

    Ed Silverman
    15 May 2012 | 7:16 am
    An FDA panel may have recommended a new Pfizer pill for rheumatoid arthritis last week, but of course, the drugmaker must still win over regulators, doctors and payers. And while Wall Street is betting the FDA will approve tofacitinib, convincing payers of its worth may prove more difficult. Although pricing will be a major determinant in coverage, it is clearly not the only factor. How so? A new survey finds that nearly 39 percent of managed care entities will require patients to first fail at least two other treatments – such as the Humira or Enbrel anti-TNF inhibitors – before…

  • Petition Demands Novartis Lower US Gleevec Price

    Ed Silverman
    15 May 2012 | 7:09 am
    As Novartis gears up for an important court case in India that can be traced to the pricing and accessibility of its Gleevec cancer med, the drugmaker is now facing a grassroots challenge in the US over the same issue. A petition was recently created on Change.org to demand that Novartis lower the price and that Congress should intervene if the drugmaker fails to do so voluntarily. “Novartis developed this drug in the 1990s. In the years since then, the price of the drug has increased astronomically. Novartis must have paid their research costs long ago, but the price just keeps rising.

  • Pharmalot… Pharmalittle… Good Morning

    Ed Silverman
    15 May 2012 | 7:03 am
    Hello, everyone, and how are you today? A spot of rain has descended on the Pharmalot corporate campus, where we have successfully hustled the short people off to their schoolhouses. And not a moment too soon, either, since we have another busy day filled with reading documents, phoning people and, hopefully, learning some interesting tidbits. We know you can relate, so here a few items to get you started. We hope your day goes well and that you accomplish much. See you soon… Cardinal Facility Banned From Shipping Controlled Substances (Associated Press) US Launches Ambitious Plan To…

  • FDA Issues New Advice For Novartis MS Pill

    Ed Silverman
    14 May 2012 | 2:56 pm
    As their European counterparts did last month, the FDA has recommended continued use of the Gilenya multiple sclerosis pill sold by Novartis, but did say the drug should carry stronger warnings about heart risks and that some patients should undergo increased monitoring. The move was largely expected after the European Medicines Agency issued a similar alert, despite arguments by a non-profit safety watchdog that further restrictions are needed. Although cardiovascular risks were known at the time of approval two years ago, the regulatory review was undertaken in response to patient deaths,…
 
  • add this feed to my.Alltop

    ePharma Rx

  • Confessions of an iPad Convert

    27 Apr 2012 | 12:08 pm
    I’ll be the first to admit: Two years ago when Apple announced its iPad, I was somewhat skeptical of its true possibilities. Was the iPad just another shiny object that the techies were excited about? Would its newness wear off? Would pharmaceutical companies adopt it at the pace of the rest of the medical community? Or would pharma take its usual “wait-and-see” approach? (And why did Apple name it after a feminine hygiene product, anyway?)It’s now April 2012. We’re on the third generation of iPad. The iPad-related RFPs keep rolling in the door here at Intouch. And just about every…

  • Bridging Gaps Between Patients and Pharma

    28 Mar 2012 | 8:32 pm
    At the CBI iPharmaConnect Conference today in Philadelphia I enjoyed hearing a panel of patients speak openly about bridging the gaps between the pharma industry and the patients who depend on their products. These women are regular contributors on HealthCentral; in the past I’ve heard similar panels from patients that are part of WeGoHealth.No matter the affiliation, the conference, or the disease state they represent, the perspectives provided from these panels are always enlightening. The room is always riveted and respectful.  The healthy reminders and a-ha moments are…

  • Two Warnings and a Wedding

    22 Mar 2012 | 9:44 am
    I was at a wedding last weekend. A beautiful outdoor wedding surrounded by family on a sunny spring day. (That's my little sister, the bride, and my Dad in the photo.) At the wedding, I had the pleasure of seeing and visiting with an uncle whom I hadn’t seen in many years. He is a retired M.D. - a family practitioner. At dinner, Uncle M. asked what I was up to these days career-wise. I explained that I worked for a marketing agency where most of our clients are pharmaceutical companies.I realized after the conversation that, in my head, I was ready to defend what I did for a…

  • What I Like About the DHC Social Media Guidelines

    6 Mar 2012 | 9:45 am
    In case you missed it, industry organization Digital Health Coalition (DHC) (on the Web here and on Facebook ) recently published self-imposed guidelines for how pharmaceutical companies should engage in social media (full disclosure: I am a “Digital Health Scholar” for the DHC, though I can’t take any credit for the guidelines).The guidelines were released at the ePharma Summit conference in New York a few weeks ago.*The DHC's “Guiding Principles and Best Practices for Companies and Users” include the below 7 edicts, (paraphrased) with key points highlighted:Regulated Healthcare…

  • I Have Some Questions

    13 Feb 2012 | 6:47 am
    Excuse me, but I have some questions.I attended ePharma Summit last week. I usually do conference wrap-up blogs but I didn't have a whole lot to report back this time aside from some select tweets. With a few exceptions, I can't say the sessions provided much insight. No super-ground-breaking ideas or mind-blowing case studies. I can't say I got any burning questions answered. For learning, I personally prefer the smaller, more interactive conferences where audience members can more easily interact and exchange ideas. Asking questions of the speaker in a room full of 600 people is just, well,…
  • add this feed to my.Alltop

    Drugsdb.com

  • Pristiq Dosage

    Carol Parker
    15 May 2012 | 11:59 pm
    Pristiq (desvenlaxafine) is mainly used to treat depression and anxiety disorder, and sometimes as chronic pain treatment for such medical conditions as diabetic neuropathy, migraines, and fibromyalgia. To produce an intended effect, Pristiq is prescribed to patients in various doses, depending on specific factors.  Standard Adult Pristiq DosageThe starting dosage for Pristiq for adults is 50 mg once daily to be taken with or without food. This goes for all medical conditions that the drug is intended to treat.Sometimes, the dose may be increased up to 400mg, although there is no proof that…

  • Prozac Dosage

    Carol Parker
    15 May 2012 | 11:43 pm
    As with any drug, the dosage of Prozac depends upon the patient’s age, weight, sex, and symptoms. Some people may be more or less susceptible to the effects of Prozac depending on genetic differences.Prozac Dosage for DepressionProzac is manufactured in capsules of 10 mg, 20 mg, and 40 mg and is taken orally.Adults and SeniorsAdults of average height and weight with no other serious health problems may begin taking Prozac in 20 mg capsules, once per day to alleviate the symptoms of depression.Elderly patients or people over age 65 may be prescribed lower dosages. After 6 weeks the…

  • Seroquel Withdrawal

    Carol Parker
    15 May 2012 | 5:45 pm
    Seroquel (Quetiapine) is a medication commonly prescribed to patients with schizophrenia or bipolar disorder. If not properly discontinued, Seroquel can cause very serious withdrawal symptoms. With careful monitoring and help from a physician, patients can discontinue their use of Seroquel safely with few withdrawal symptoms.Seroquel Withdrawal SymptomsSeroquel helps to stabilize brain chemistry by blocking the chemical receptors of serotonin, dopamine and adrenergic. The brain becomes used to having a high level of these natural chemicals within the brain at all times. If Seroquel is stopped…

  • Seroquel and Alcohol

    Carol Parker
    15 May 2012 | 5:38 pm
    Alcohol use and Seroquel can be a dangerous combination, and patients taking Seroquel should be educated about the possible effects.Can I Drink While on Seroquel?Most doctors recommend that patients who have a mental illness, such as schizophrenia or bipolar disorder, not drink at all. The alcohol can trigger depressive states and some patients may turn to alcohol to self medicate. It is also strongly suggested that patients taking Seroquel not partake in alcohol at all. Some patients may choose to discuss their alcohol consumption with their doctor, and the doctor may agree to a moderate or…

  • Seroquel and Weight Gain

    Carol Parker
    15 May 2012 | 5:33 pm
    Up to 23 percent of all people who take Seroquel report weight gain as a side effect of the drug.  The weight gained is on average about 7 percent of the patient's total body weight.AstraZeneca, the company that produces Seroquel, recognizes that one of the most common side effects of Seroquel is weight gain. Unfortunately, there aren’t many ideas on why the medication causes the response that it does. Some patients have said that after taking their dose of Seroquel they experience extreme hunger, even after eating a full meal. This is something that Seroquel patients can be aware of and…
  • add this feed to my.Alltop

     Health Care Insights - From Policy to Practice

  • MDRP 2012 Session Spotlight: Point/Counterpoint: Impact of the Election on Healthcare Reform—What’s Coming and How Will it Affect the Pharmaceutical Industry?

    9 May 2012 | 3:24 pm
    The government has the power to completely overhaul the way the pharmaceutical industry does business. With healthcare reform, we saw a huge increase in the number of people eligible for Medicaid and the 340B program, a redefinition of pricing calculations, and the addition of Managed Medicaid to the rebate system. All of these things had a huge impact on the financials of each manufacturer. Healthcare reform is a hot button topic at every election and this year will likely be no different. The outcome of either candidate’s election could mean a slew of new laws on Medicaid or Medicare,…

  • There is Something For Everyone at the 17th Annual Medicaid Drug Rebate Program Summit!

    7 May 2012 | 11:40 am
    The government reimbursement landscape is constantly changing. Policy, operations, and data challenges are in constant influx, and each change affects the pharmaceutical and biotechnology professionals working in the public reimbursement space. What has remained constant for 17 years, is that IIR's Medicaid Drug Rebate Program Summit, is the go to event for everyone in the industry.  This year, it will take place September 10-12 in Chicago, IL. Every year the audience grows and this year we’ve expanded the program to ensure that MDRP has something for everyone. Are you NEW to MDRP? •…

  • Full Speed Ahead!

    2 May 2012 | 7:16 am
    By Richard Yadon, President and CEO, Managed Medicaid Services, Host of Medicaid Matters talk show Yesterday I visited the Navy Memorial in Washington DC. Being a Navy veteran it has special significance to me. Being there brought back a flood of memories from my days of active duty and reserve service. Those days weren’t always easy. I can remember being on the naval gunfire line off the coast of Beirut supporting the Marines at the airport in 1983. This was just a few day after the devastating terrorist attack which killed over 200 Marines. Nobody knew if or when something bigger might be…

  • #MMCC 2012 Live: Thurston Howell III vs. the Professor

    1 May 2012 | 2:55 pm
    By Richard Yadon, President & CEO, Managed Medicaid Services and Host of Medicaid Matters talk show Thurston Howell III vs the Professor is how political analyst and commentator Paul Begala characterized the upcoming presidential election during his comments at the Medicaid Managed Care Congress today. This was in response to a question from the audience about whether health care is a Right or a Privilege. As pointed out by Mr. Begala, it is not a constitutionally guaranteed right; however, most Americans recognize that access to health care is the right thing to provide. The real…

  • #MMCC2012: The ACA as an Opportunity for Pharma Companies to Increase the Proper Use of Medication

    1 May 2012 | 6:43 am
    Monday at the 20th annual Medicaid Managed Care Congress, Cindy Pigg, SVP of Pharmacy at Magellan Medicaid Administration shared that the ACA is the largest opportunity for the pharmaceutical industry since Medicare Part D. By 2019, there’s expected to be more than 25 billion dollars spent on pharmaceutical drugs. This is a huge increase, especially considering during the recession, a lot less people went to the doctor’s office, and of those, a fair amount got prescriptions but never got them filled. Therefore, as a part of the ACA, pharmaceutical organizations have not only the…
 
Log in